Contact Lens Discomfort Clinical Trial
Official title:
The Effect and Duration of Efficacy of Eyelid Margin Debridement on Signs and Secretions of Eyelids, Tear Film and Discomfort in Contact Lens Wearers
In this study, clinical variables related to eyelids that potentially have an effect on contact lens discomfort will be investigated such as eyelid signs and secretions, eyelid sensitivity, eyelid microbiome, Demodex infestation and tear film properties. The main aim of this study is to understand the duration of efficacy of debridement of the eyelid margin and its impact on various eyelid signs (such as lid wiper epitheliopathy, lid-parallel conjunctival folds, eyelid sensitivity, meibomian gland morphology and meibum secretions, palpebral conjunctival reaction, eyelid microbiome and Demodex infestation, tear properties (both biophysical properties such as tear volume, tear meniscus height, tear evaporation, tear osmolarity and tear breakup time; and biochemical properties that are tear lipid analysis). To observe these variables, this study employs a cross-sectional design to study the effect of treatment at three instances, that is at baseline and two follow-up visits.
Contact lens discomfort (CLD) is a substantial problem experienced frequently by contact lens
wearers and it is the primary factor associated with permanent discontinuation of lens wear.
Studies report that between 43% and 72% of contact lens wearer's dropout due to discomfort.
Reducing the number of contact lens (CL) patient dropouts has been a continuing challenge for
eye care professionals. With more than 125 million contact lens wearers around the world,
patient discontinuations can have a considerable economic impact on an eye care practice.
Definition: Contact lens discomfort is a condition characterized by episodic or persistent
adverse ocular sensations related to lens wear, either with or without visual disturbance,
resulting from reduced compatibility between the contact lens and the ocular environment,
which can lead to decreased wearing time and discontinuation of contact lens wear.
Inferences from our earlier study (HC15119) showed that eyelid margin debridement
significantly improves eyelid signs, tear film properties and comfort in contact lens
wearers. But the previous study did not consider the duration of efficacy as the subjects
were only followed up once after 7-10days from treatment. Observing subjects more frequently
will help us understand the duration of efficacy of debridement therapy. Also, the previous
study did not examine the biochemical changes to tear film lipids that are produced by the
eyelids.
It is hypothesized that debridement of eyelid margins improves lipid secretions that then
help to form a stable lipid layer over ocular surface, thereby improving the tear evaporation
dynamics and comfort in contact lens wearers.
Aim: The aim of the study is to observe the duration of efficacy of debridement of the eyelid
margins in improving secretions from eyelid glands and whether the debridement helps to form
a stable tear film over ocular surface, thereby improving comfort in contact lens wearers.
Objectives: To determine the effect of BlephEx - debridement therapy (an in-office eyelid
treatment) on eyelid signs and secretions, tear film and contact lens discomfort.
To observe differences in discomfort in contact lens wearers To determine the duration of
efficacy of BlephEx debridement therapy in contact lens wearers, by following up after 12-15
days and 22-25days from the baseline (Treatment) visit.
Methods: The study employs cross-sectional study design, to observe the effect of treatment
at three instances, one baseline (treatment) visit and two follow-up visits. At the baseline
visit, informed consent will be obtained from the subjects and assessment of the study
variables will be performed. Participants will undergo treatment on the same day with
BlephEx. At baseline, the measurements are performed prior to treatment to record preliminary
scores and then treatment is performed. Participants are asked to return to the clinic for
follow-up visits during which no treatment will be performed, but variables are assessed to
determine the difference from baseline measurements. The 2nd visit will be after 12 -16 days
after the baseline visit. The last follow-up will be 22-26 days after the baseline visit. All
study variables will be assessed during all three visits to the clinic.
Treatment Procedure: BlephEx is an instrument that contains a handpiece used to spin a
medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf
and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used
for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.
Lid Hygenix is a commercially available formulated hypoallergenic foam cleanser will be used
to moisten the BlephEx debridement tips.
Both the products are commercially available. The procedure is safe, painless and regularly
performed by optometrists.
'Participant information sheet and informed consent' and 'web-based survey for the end of the
day discomfort rating' will be sent out in the form of an email. Participants who are
interested in participation will respond to the survey and results will be used only after
the subject signs the informed consent in the presence of the investigator, during the
baseline visit. This survey response will be used as baseline data for the end of the day
discomfort.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03682809 -
Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort
|
Phase 4 | |
Completed |
NCT05416528 -
Chinese Translation and Validation of the 8-item Contact Lens Dry Eye Questionnaire (CLDEQ-8)
|
||
Completed |
NCT05548491 -
Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)
|
Phase 2 | |
Active, not recruiting |
NCT03652337 -
Meibomian Gland Dysfunction Management
|
N/A | |
Not yet recruiting |
NCT05801991 -
Neurolens and Contact Lens Discomfort
|
N/A | |
Completed |
NCT03994406 -
Prolongation of Contact Lens Comfortable Wear Duration by CLM2 Topical Gel
|
Phase 2 | |
Completed |
NCT02848222 -
Pilot Study for Investigating the Effect of the Bruder Eye Hydrating Compress on Contact Lens Discomfort in Contact Lens Wearers
|
N/A | |
Completed |
NCT03686878 -
Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness
|
Phase 4 |